Methylprednisolone pulse therapy in two clinical types of crescentic glomerulonephritis

Internal Medicine

Volumn 37, Issue 7, 1998, Pages 585-591

  Takeda, Shin Ichi ^a,d   Kida, Hiroshi ^b   Yokoyama, Hitoshi ^c   Takazakura, Eisuke ^a   Kobayashi, Ken Ichi ^c  

^a Kurobe City Hospital   (Japan)

^b Int Med of Kanazawa Natl Hospital   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d Kurobe City Hospital   (Japan)

Author keywords

Acute type; Insidious type

Indexed keywords

METHYLPREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLOMERULONEPHRITIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

EID: 0031828103     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.585     Document Type: Article

References (27)

1. Bacani RA, Velasquez F, Karter A, Pirani CL, Pollak VE. Rapidly progressive (nonstreptococcal) glomerulonephritis. Ann Intern Med 69: 463, 1968.
2. Sonsino E, Nabarra B, Kazatchkine M, Hinglais N, Kreis H. Extracapillary proliferative glomerulonephritis so-called malignant glomerulonephritis. Adv Nephrol Necker Hosp 2: 121, 1972.
3. Beirne GJ, Wagnild JP, Zimmerman SW, Macken PD, Burkholder PM. Idiopathic crescentic glomerulonephritis. Medicine (Baltimore) 56: 349, 1977.
4. Takeda S, Kida H, Yokoyama H, Tomosugi N, Kobayashi K. Two distinct types of crescentic glomerulonephritis Clin Nephrol 37: 285, 1992.
5. Cole BR, Brocklebank JT, Kienstra RA, Kissane JM, Robson AM. "Pulse" methylprednisolone therapy in the treatment of severe glomerulonephritis. J Pediatr 88: 307, 1976.
6. O'Neill WM Jr, Etheridge WB, Bloomer HA. High-dose corticosteroids. Their use in treating idiopathic rapidly progressive glomerulonephritis. Arch Intern Med 139: 514, 1979.
7. Oredugba O, Mazumdar DC, Meyer JS, Lubowitz H. Pulse methylprednisolone therapy in idiopathic, rapidly progressive glomerulonephritis. Ann Intern Med 92: 504, 1980.
8. Stevens ME, McConnell M, Bone JM. Aggressive treatment with pulse methylprednisolone or plasma exchange is justified in rapidly progressive glomerulonephritis. Proc Eur Dial Transplant Assoc 19: 724, 1982.
9. Ferraris JR, Gallo GE, Ramirez J, Iotti R, Gianantonio C. 'Pulse' methylprednisolone therapy in the treatment of acute crescentic glomerulonephritis. Nephron 34: 207, 1983 (letter).
10. Bolton WK, Sturgill BC. Methylprednisolone therapy for acute crescentic rapidly progressive glomerulonephritis. Am J Nephrol 9: 368, 1989.
11. de Glas-Vos JW, Krediet RT, Arisz L. Methylprednisolone pulse therapy in rapidly progressive glomerulonephritis. Neth J Med 38: 96, 1991.
12. Levy JB, Winearls CG. Rapidly progressive glomerulonephritis: What should be first-line therapy? Nephron 67: 402, 1994 (review).
13. Glassock RJ, Cohen AH, Adler SG. Primary glomerular diseases. in: The Kidney, Brenner BM, Ed. WB Saunders, Philadelphia, 1996, p. 1404.
14. World Health Organization (WHO) Monograph. Glossary of terms. in: Renal Disease. Classification and Atlas of Glomerular Diseases. Churg J, Bernstein J, Glassock RJ, Eds. Igaku-Shoin, Tokyo, 1995, p. 3.
15. McPhaul JJ Jr, Dixon FJ. The presence of antiglomerular basement membrane antibodies in peripheral blood. J Immunol 103: 1168, 1969.
16. Whitworth JA, Morel-Maroger L, Mignon F, Richet G. The significance of extracapillary proliferation. Clinicopathological review of 60 patients. Nephron 16: 1, 1976.
17. Couser WG. Rapidly progressive glomerulonephritis: Classification, pathogenetic mechanisms, and therapy. Am J Kidney Dis 11: 449, 1988 (in-depth review).
18. Morrin PAF, Hinglais N, Nabarra B, Kreis H. Rapidly progressive glomerulonephritis. A clinical and pathologic study. Am J Med 65: 446, 1978.
19. Southwest Pediatric Nephrology Study Group. A clinico-pathologic study of crescentic glomerulonephritis in 50 children. A report of the Southwest Pediatric Nephrology Study Group. Kidney Int 27: 450, 1985.
20. Heilman RL, Offord KP, Holley KE, Velosa JA. Analysis of risk factors for patient and renal survival in crescentic glomerulonephritis. Am J Kidney Dis 9: 98, 1987.
21. Yokoyama H, Takabatake T, Takaeda M, et al. Up-regulated MHC-class II expression and γ-IFN and soluble IL-2R in lupus nephritis. Kidney Int 42: 755, 1992.
22. Wada T, Yokoyama H, Tomosugi N, et al. Detection of urinary interleukin-8 in glomerular diseases. Kidney Int 46: 455, 1994
23. Wysenbeek AJ, Leibovici L, Zoldan J. Acute central nervous system complications after pulse steroid therapy in patients with systemic lupus erythematosus. J Rheumatol 17: 1695, 1990.
24. Moses RE, McCormick A, Nickey W. Fatal arrhythmia after pulse methylprednisolone therapy. Ann Intern Med 95: 781, 1981 (letter).
25. Sakemi T, Fujimoto S, Fujimi S, Yamamoto Y, Etoh T, Yamaguchi M. Difference between renal failure associated with methylprednisolone pulse therapy and deterioration of renal function unrelated to methylprednisolone therapy. Am J Nephrol 13: 132, 1993.
26. Keller F, Oehlenberg B, Kunzendorf U, Schwarz A, Offermann G. Long-term treatment and prognosis of rapidly progressive glomerulonephritis. Clin Nephrol 31: 190, 1989.
27. Bruns FJ, Adler S, Fraley DS, Segel DP. Long-term follow-up of aggressively treated idiopathic rapidly progressive glomerulonephritis. Am J Med 86: 400, 1989.